Tests and monitoring

Genetic primary bile acid malabsorption can produce IBD-like symptoms and may be missed in children labeled with Crohn's disease; recognizing PBAM could change testing and management for some patients.

Understanding and quantifying placebo-driven endoscopic changes can improve design and interpretation of Crohn’s disease trials, which may ultimately speed development of effective therapies and clarify who benefits from...

Capsule endoscopy can be helpful for small-bowel assessment in Crohn’s disease but carries a risk of retention when strictures are present. Retained capsules may be asymptomatic yet still require surgery, so better...

PSC is rare in the general population but substantially more common in people with IBD, particularly ulcerative colitis, and it raises long-term hepatobiliary risks including cholangiocarcinoma—so knowing how often PSC...

Faster, accurate diagnosis can let people with Crohn's disease start appropriate treatment sooner and help avoid complications from ongoing inflammation. The article outlines common presenting symptoms and recommended...

This trial directly tests common clinical strategies for managing loss of response to ustekinumab in Crohn’s disease. The findings may change whether doctors routinely escalate to 4-weekly dosing after an IV reinduction,...

Growth and nutrition are major concerns in children with Crohn’s disease. This study suggests perianal disease and common inflammatory and nutritional markers may help predict which children are at higher risk for...

The study pinpoints a genetic cause (BIRC3 variants) that disrupts a TNF/RIPK1 immune pathway linked to Crohn’s disease, suggesting a targetable mechanism. That could help doctors match patients to treatments and guide...

Diet-based induction options matter for children because EEN can be hard to tolerate. This study finds CDED (with partial enteral nutrition) performs similarly to EEN for inducing remission and mucosal healing in...

Noninvasive tests at 3 months after ileocecal resection (ultrasound + fecal calprotectin) may identify patients at high risk of endoscopic recurrence by 6 months. That could help avoid or target postoperative endoscopy...

Terminal ileitis affects the terminal ileum and is most commonly linked to Crohn’s disease, so people with IBD or abdominal symptoms should know it can cause pain, diarrhea, and, in some cases, serious complications.

Scientists found BIRC3 gene changes that cause Crohn’s in some patients and showed those changes drive inflammation through the RIPK1/TNF pathway. That suggests a new, druggable pathway and may help predict who benefits...

This study identifies a specific genetic cause (BIRC3 variants) that drives inflammation through the RIPK1/TNF pathway and points to an existing drug target (RIPK1). If validated, the finding could help match patients to...

This large real-world study suggests GLP-1 receptor agonists used in adults with Crohn’s disease and obesity were associated with lower healthcare use and lower subsequent TNF inhibitor use at 1 and 5 years, findings...

This study reports real-world effectiveness of risankizumab for refractory Crohn's disease, showing many patients achieved steroid-free remission. The results are relevant for people weighing treatment options after...

This study suggests risankizumab may improve quality of life and reduce common symptoms (fatigue, mood, urgency) more than ustekinumab for patients with moderate-to-severe Crohn’s disease who didn’t respond to anti-TNF...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

A reliable, accurate intestinal ultrasound could make routine monitoring easier, faster, and less costly than repeated MRI for people with Crohn’s disease. The study shows strong agreement between ultrasound scores and...

The atlas maps which genes and cell types are different in Crohn's disease, offering clues about why inflammation persists and pointing to specific immune pathways (like JAK/STAT) that are already drug targets. The...

Pregnancy planning affects disease and pregnancy outcomes in Crohn’s. Staying in remission and maintaining needed IBD medications during pregnancy reduces risks to both mother and baby, while stopping certain drugs...

This study maps gene activity in over a million gut cells and finds lasting molecular changes in stem cells after inflammation, which could help explain recurrence and guide future research toward new drug targets.

This study suggests that regional differences in how often and how early advanced drugs are used didn’t change 10-year rates of surgery, hospitalization, or progression to complicated Crohn’s disease in this cohort.

The article outlines complications that can come from Crohn’s disease, many of which may need tests, medication, or surgery. Knowing these helps you recognize warning signs and talk with your care team about prevention...

Long-term (five-year) data suggest guselkumab may provide sustained clinical and endoscopic benefit for people with moderate-to-severe Crohn’s disease, which is important for disease control and reducing need for...

Cure8 found this source from caledonianrecord.com, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Crohn's disease, and Vedolizumab. Open the original article for the full details.

Long-term data help patients and clinicians understand whether a biologic maintains benefit and safety over years. Sustained clinical remission and endoscopic healing are important outcomes linked to better long-term...

This study suggests surgery can help heal severe, noncontiguous (metastatic) skin manifestations of Crohn’s disease when medical therapy alone isn’t enough. It highlights that realistic healing may take many months and...

Routine care and sensible lifestyle choices can reduce flares and complications in Crohn's disease. Missing specialist care, stopping meds, smoking, poor diet, or skipping appointments are common, avoidable risks.

Based on the title and source metadata, this appears to be a guideline related to Crohn's disease, Inflammatory bowel disease, and Intestinal ultrasound. The original article is from springermedicine.com.

New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...

The study identifies colonic gene-expression programs that correlate with treatment failure, higher surgery rates, and perianal disease in Crohn’s — findings that could guide future prognostic tests and targeted...

Some people with moderate-to-severe Crohn’s who don’t fully respond to one advanced therapy may hear about adding a second drug. This article explains when clinicians might consider that approach, the potential benefits...

This study suggests acne is a common real-world side effect of upadacitinib for IBD and can affect treatment decisions and quality of life, especially for younger patients.

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. Open the original article for the full...

If you had bowel surgery for Crohn’s disease and develop postoperative anastomotic bleeding, this study suggests endoscopic treatment can stop bleeding in most patients and may avoid another operation. Patients who need...

Surgical technique after ileocolic resection may influence how likely Crohn’s disease is to come back near the anastomosis.

This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.

Mucosal healing is a treatment goal that aims to stop internal intestinal inflammation, not just symptoms. Achieving mucosal healing is linked with fewer hospitalizations, less need for surgery, and lower rates of...

How “moderate” IBD is defined affects who is enrolled in trials, who is offered advanced therapies, and how clinicians make treatment decisions. Inconsistent definitions could delay appropriate care for people who might...

This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.

Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.

A real patient story showing how Crohn’s disease can start with vague symptoms and take years to diagnose may help others recognize when to seek further evaluation. It also describes common diagnostic tests used for IBD.

This research suggests genetic risk scores could help identify people with IBD who are more likely to have severe disease, which might eventually inform earlier monitoring or treatment decisions. It’s a step toward more...

Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from...

Based on the title and source metadata, this appears to be a low information aggregator related to Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. The original article is from pressreader.com.

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Procedures and surgery. The original article is from msn.com.

After bowel resection, Crohn’s often returns quietly at the surgical join (anastomosis). Early, planned monitoring can detect inflammation before symptoms appear and help prevent symptomatic recurrence or repeat surgery.

The study suggests a blood cytokine (CXCL9) could help noninvasively detect intestinal inflammation in Crohn’s disease, which might one day reduce reliance on colonoscopy for monitoring disease activity.